Iowanews Headlines

Gastrointestinal Stromal Tumor Market

The Gastrointestinal Stromal Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastrointestinal Stromal Tumor pipeline products will significantly revolutionize the Gastrointestinal Stromal Tumor market dynamics.

DelveInsight’s “Gastrointestinal Stromal Tumor Market Insight, Epidemiology And Market Forecast – 2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Gastrointestinal Stromal Tumor market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Visit Gastrointestinal Stromal Tumor Market Insights

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report:

• Gastrointestinal Stromal Tumor market size was highest in the United States among the 7MM countries

• Gastrointestinal Stromal Tumor Companies:Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor Inc., DNAtrix Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx Inc., Allarity Therapeutics

• Gastrointestinal Stromal Tumor Therapies: Gleevec (imatinib mesylate), Stivarga (regorafenib), Sutent (sunitinib malate), Ayvakit (avapritinib), Qinlock (ripretinib), Rozlytrek (entrectinib), Vitrakvi (larotrectinib), Belzutifan, CGT9486, DCC-3116, UCB4594, Famitinib, DS 6157, PLX9486, Anlotinib, Masitinib, Intuvax, Dovitinib, Ipilimumab, L-carnitine, Pazopanib, Nilotinib, HQP1351, PDR001, Ponatinib, MEK162, Crenolanib besylate, XmAb18087, TNO155, DNX-2440, Palbociclib, Cabozantinib, Pamufetinib, THE-630, IDRX-42, IDRX-73, among others.

Gastrointestinal Stromal Tumor Overview

A gastrointestinal stromal tumor (GIST) is a rare type of cancer that starts in the digestive system, most often in the stomach or small intestine. These tumors grow from specialized cells in the wall of the digestive tract called interstitial cells of Cajal. Symptoms are often non-specific and may include abdominal pain, bleeding in the stool or vomit, and a feeling of fullness, but small GISTs may not cause any symptoms at all. Diagnosis involves imaging tests like CT scans and MRIs, followed by a biopsy, and treatment typically involves surgery, sometimes combined with targeted drug therapy

Gastrointestinal Stromal Tumor Market

The dynamics of the Gastrointestinal Stromal Tumor market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2025-2034.

Gastrointestinal Stromal Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastrointestinal Stromal Tumor Epidemiology Segmentation:

The Gastrointestinal Stromal Tumor market report offers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Gastrointestinal Stromal Tumor Incident Cases

• Gastrointestinal Stromal Tumor Gender-specific Incident Cases

• Gastrointestinal Stromal Tumor Age-specific Incident Cases

• Gastrointestinal Stromal Tumor Mutation-specific Incident Cases

• Gastrointestinal Stromal Tumor Stage-specific Incident Cases

• Gastrointestinal Stromal Tumor Treatable Cases by Line of Therapies

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Epidemiological Insights

Gastrointestinal Stromal Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastrointestinal Stromal Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Gastrointestinal Stromal Tumor treatment, visit @ Gastrointestinal Stromal Tumor Medications

Gastrointestinal Stromal Tumor Therapies and Key Companies

• Gleevec (imatinib mesylate): Novartis

• Sutent (sunitinib malate): Pfizer

• Stivarga (regorafenib): Bayer, Amgen

• Ayvakit (avapritinib): Blueprint Medicines, CStone Pharmaceuticals

• Qinlock (ripretinib): Deciphera Pharmaceuticals

• Rozlytrek (entrectinib): Roche

• Vitrakvi (larotrectinib): Bayer, Loxo Oncology

• Belzutifan: Merck

• CGT9486: Cogent Biosciences

• DCC-3116: Deciphera Pharmaceuticals

• UCB4594: UCB

• Famitinib: Jiangsu Hengrui Pharmaceuticals

• DS 6157: Daiichi Sankyo

• PLX9486: Plexxikon (Daiichi Sankyo)

• Anlotinib: Chia Tai Tianqing Pharmaceutical

• Masitinib: AB Science

• Intuvax (Ilixadencel): Immunicum

• Dovitinib: Novartis, Allarity Therapeutics

• Ipilimumab: Bristol-Myers Squibb

• L-carnitine: Various (supplement, not a branded therapy)

• Pazopanib: Novartis

• Nilotinib: Novartis

• HQP1351: Ascentage Pharma

• PDR001: Novartis

• Ponatinib: Takeda

• MEK162 (Binimetinib): Novartis

• Crenolanib besylate: Arog Pharmaceuticals

• XmAb18087: Xencor

• TNO155: Novartis

• DNX-2440: DNAtrix

• Palbociclib: Pfizer

• Cabozantinib: Exelixis

• Pamufetinib: Taiho Pharmaceutical

• THE-630: Theseus Pharmaceuticals

• IDRX-42: IDRx

• IDRX-73: IDRx

Gastrointestinal Stromal Tumor Market Drivers

• Growing incidence of GIST, driven by improved diagnostic capabilities and wider use of imaging/endoscopy.

• Advances in molecular testing, enabling precise identification of KIT, PDGFRA, and other mutations for targeted therapy selection.

• Strong adoption of targeted therapies, including TKIs such as imatinib, sunitinib, and newer agents for resistant mutations.

• Rising prevalence of treatment-resistant and metastatic GIST, increasing demand for next-line therapies.

• Expansion of precision oncology supporting mutation-guided treatment approaches.

• Development of next-generation TKIs and novel mechanisms, improving outcomes in refractory or rare mutation subtypes.

• Increased healthcare spending and greater access to oncology treatments globally.

• Growing clinical trial activity exploring combination regimens and immunotherapies for GIST.

• Patient advocacy and awareness efforts promoting earlier diagnosis and clinical trial participation.

• Advancements in surgical techniques that improve treatment outcomes and expand patient eligibility for multimodal therapy.

Gastrointestinal Stromal Tumor Market Barriers

• High treatment costs, especially for long-term use of targeted therapies and next-generation TKIs.

• Development of drug resistance, limiting the long-term effectiveness of existing treatments such as imatinib.

• Limited therapeutic options for rare and resistant mutations (e.g., PDGFRA D842V, SDH-deficient GIST).

• Dependence on mutation testing, which may not be widely available in resource-limited regions.

• Adverse effects of TKIs, leading to treatment discontinuation or dose reduction.

• Late-stage diagnosis in many patients, reducing the effectiveness of available therapies.

• High cost and complexity of clinical trials, particularly for rare mutation subsets and refractory disease.

• Slow uptake of newer therapies due to physician familiarity with established TKIs.

• Reimbursement challenges in certain markets for high-cost targeted agents.

• Limited awareness of GIST, as it remains a relatively rare cancer often misdiagnosed initially.

Scope of the Gastrointestinal Stromal Tumor Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

• Key Gastrointestinal Stromal Tumor Companies: Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor Inc., DNAtrix Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx Inc., Allarity Therapeutics

• Key Gastrointestinal Stromal Tumor Therapies: Gleevec (imatinib mesylate), Stivarga (regorafenib), Sutent (sunitinib malate), Ayvakit (avapritinib), Qinlock (ripretinib), Rozlytrek (entrectinib), Vitrakvi (larotrectinib), Belzutifan, CGT9486, DCC-3116, UCB4594, Famitinib, DS 6157, PLX9486, Anlotinib, Masitinib, Intuvax, Dovitinib, Ipilimumab, L-carnitine, Pazopanib, Nilotinib, HQP1351, PDR001, Ponatinib, MEK162, Crenolanib besylate, XmAb18087, TNO155, DNX-2440, Palbociclib, Cabozantinib, Pamufetinib, THE-630, IDRX-42, IDRX-73, and others.

• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies

• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Gastrointestinal Stromal Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastrointestinal Stromal Tumor Market Access and Reimbursement

Discover more about therapies set to grab major Gastrointestinal Stromal Tumor market share @ Gastrointestinal Stromal Tumor Treatment Landscape

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Gastrointestinal Stromal Tumor Market Overview at a Glance

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Gastrointestinal Stromal Tumor Background and Overview

8. Gastrointestinal Stromal Tumor Treatment

9. Gastrointestinal Stromal Tumor Epidemiology and Patient Population in the 7MM

10. Gastrointestinal Stromal Tumor Patient Journey

11. Gastrointestinal Stromal Tumor Marketed Drug

12. Gastrointestinal Stromal Tumor Emerging Drugs

13. Gastrointestinal Stromal Tumor: 7MM Analysis

14. Unmet needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services